Racial disparities and glioblastoma recurrence; a double impact for increased patient mortality: a correspondence

Excerpt

Glioblastoma (GBM) remains an incurable and devastating disease, with a median survival rate estimated at 14 months, despite the application of the gold standard treatment—maximal safe resection followed by adjuvant temozolomide (TMZ) and radiation. While GBM typically appears on imaging as a heterogeneous enhancing mass featuring a central necrotic core surrounded by peritumoral edema, diagnosis relies on histopathological findings. However, the assessment of molecular markers, such as isocitrate dehydrogenase (IDH) mutations and O6-methylguanyl DNA methyltransferase (MGMT) promoter methylation, along with broader molecular profiling, is increasingly used for prognostic subclassification and to tailor treatment approaches [1]. …